

Editorial

Mediterranean Diet and Soy Isoflavones for Integrated Management of the Menopausal Metabolic Syndrome

Herbert Ryan Marini 

Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy; hrmarini@unime.it; Tel.: +39-(090)-221-3328; Fax: +39-(090)-221-7001

The transition from premenopause to postmenopause is associated with the development of multiple elements of Metabolic Syndrome (MetS) [1–3]. The typical features of the syndrome [4,5] could be related to a progressive estrogen deficiency resulting in metabolic consequences of central fat redistribution associated with progressive testosterone predominance [2,3]. These changes lie with a dramatic increase in the risk of cardiovascular disease (CVD), which is the leading cause of death in women 65 years and older [3]. Prevention and treatment of MetS in menopause should focus on lifestyle modifications (i.e., dietary style and physical activity) [6].

Isoflavones and related compounds act through the estrogen receptors (ERs) and are often used in postmenopausal women [7]. Our research group previously showed that genistein, which is the most abundant and active isoflavone in soy, acting as a natural selective ER- β modulator [8], positively regulates bone metabolism [9,10], improves endothelium-dependent dilation [11], and reduces vasomotor symptoms [12] and some cardiovascular risk markers [13,14], without harmful side effects on thyroid [15] and reproductive tissues, including breast tissue [16]. Additionally, one year of treatment with pure genistein (54 mg/day) ameliorated cardiac and endothelial functioning [17,18], as well as improved surrogate endpoints associated with risk for diabetes and CVD in postmenopausal women with MetS [19].

The relationship between soy products, isoflavones, diet, and CVD has become a controversial topic.

Among plant-based diets, current evidence suggests that the Mediterranean and vegetarian diets are associated with numerous health benefits, including a lower risk of CVD [20]. These positive effects may be explained by their high content of dietary fiber, complex carbohydrates, vitamins, minerals, polyunsaturated fatty acids, and phytochemicals [20]. Specifically, a recent work by Dinu and colleagues of “The Working Group “Young Members” of the Italian Society of Human Nutrition (SINU)” suggested that the “Mediterranean diet had the strongest and most consistent evidence of a beneficial effect on both anthropometric parameters and cardiometabolic risk factors” [21].

So far, a very recent observational research published in *Circulation* by Le Ma and coworkers [22] indicated that “higher intake of isoflavones and tofu was associated with a moderately lower risk of developing Coronary Heart Disease, and in women the favorable association of tofu were more pronounced in young women or postmenopausal women without hormone use”; consequently, it appears that an adequate intake of isoflavones and/or soy products such as tofu can be integrated into healthy plant-based diets, adding nutritional support in the prevention of CVD [23]. However, as remarked by Carnethon and Khan in their editorial on time [24], “there are critical limitations of observational studies of diet that warrant caution about making causal statements”.

Undoubtedly, the question is interesting, opening new intriguing fields studying the effects of the combination “Mediterranean diet” and soy isoflavones intake, with the ambitious target to better define in post-menopausal women [25] the relationship between



Citation: Marini, H.R. Mediterranean Diet and Soy Isoflavones for Integrated Management of the Menopausal Metabolic Syndrome. *Nutrients* **2022**, *14*, 1550. <https://doi.org/10.3390/nu14081550>

Received: 26 March 2022

Accepted: 7 April 2022

Published: 8 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

diet, bioactive foods, and nutraceuticals then counteracting, through lifestyle modifications, the constellation of risk factors that characterize MetS.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of Interest: The author declares no actual or potential competing financial interests.

References

- Janssen, I.; Powell, L.H.; Crawford, S.; Lasley, B.; Sutton-Tyrrell, K. Menopause and the metabolic syndrome: The Study of Women's Health Across the Nation. *Arch. Intern. Med.* **2008**, *168*, 1568–1575. [\[CrossRef\]](#)
- Stefanska, A.; Bergmann, K.; Sypniewska, G. Metabolic Syndrome and Menopause: Pathophysiology, Clinical and Diagnostic Significance. *Adv. Clin. Chem.* **2015**, *72*, 1–75.
- Pu, D.; Tan, R.; Yu, Q.; Wu, J. Metabolic syndrome in menopause and associated factors: A meta-analysis. *Climacteric* **2017**, *20*, 583–591. [\[CrossRef\]](#)
- Kassi, E.; Pervanidou, P.; Kaltsas, G.; Chrousos, G. Metabolic syndrome: Definitions and controversies. *BMC Med.* **2011**, *9*, 48. [\[CrossRef\]](#)
- Saklayen, M.G. The global epidemic of the metabolic syndrome. *Curr. Hypertens. Rep.* **2018**, *20*, 12. [\[CrossRef\]](#)
- Teede, H.J.; Lombard, C.; Deeks, A.A. Obesity, metabolic complications and the menopause: An opportunity for prevention. *Climacteric* **2010**, *13*, 203–209. [\[CrossRef\]](#)
- North American Menopause Society. The role of soy isoflavones in menopausal health: Report of The North American Menopause Society/Wulf, H. Utian Translational Science Symposium in Chicago, IL (October 2010). *Menopause* **2011**, *18*, 732–753. [\[CrossRef\]](#)
- Kuiper, G.G.; Lemmen, J.G.; Carlsson, B.; Corton, J.C.; Safe, S.H.; Van Der Saag, P.T.; Van Der Burg, B.; Gustafsson, J.Å. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β . *Endocrinology* **1998**, *139*, 4252–4263. [\[CrossRef\]](#)
- Marini, H.; Minutoli, L.; Polito, F.; Bitto, A.; Altavilla, D.; Atteritano, M.; Gaudio, A.; Mazzaferro, S.; Frisina, A.; Frisina, N.; et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: A randomized trial. *Ann. Intern. Med.* **2007**, *146*, 839–847. [\[CrossRef\]](#)
- Arcoraci, V.; Atteritano, M.; Squadrito, F.; D'Anna, R.; Marini, H.; Santoro, D.; Minutoli, L.; Messina, S.; Altavilla, D.; Bitto, A. Antiosteoporotic Activity of Genistein Aglycone in Postmenopausal Women: Evidence from a Post-Hoc Analysis of a Multicenter Randomized Controlled Trial. *Nutrients* **2017**, *22*, 179. [\[CrossRef\]](#)
- Squadrito, F.; Altavilla, D.; Crisafulli, A.; Saitta, A.; Cucinotta, D.; Morabito, N.; D'Anna, R.; Corrado, F.; Ruggeri, P.; Frisina, N.; et al. Effect of genistein on endothelial function in postmenopausal women: A randomized, double-blind, controlled study. *Am. J. Med.* **2003**, *114*, 470–476. [\[CrossRef\]](#)
- D'Anna, R.; Cannata, M.L.; Atteritano, M.; Cancellieri, F.; Corrado, F.; Baviera, G.; Triolo, O.; Antico, F.; Gaudio, A.; Frisina, N.; et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: A 2-year randomized, double-blind, placebo-controlled study. *Menopause* **2009**, *16*, 301–306. [\[CrossRef\]](#)
- Atteritano, M.; Marini, H.; Minutoli, L.; Polito, F.; Bitto, A.; Altavilla, D.; Mazzaferro, S.; D'Anna, R.; Cannata, M.L.; Gaudio, A.; et al. Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: A two-year randomized, double blind, placebo-controlled study. *J. Clin. Endocrinol. Metab.* **2007**, *92*, 3068–3075. [\[CrossRef\]](#)
- Marini, H.R.; Bitto, A.; Altavilla, D.; Burnett, B.; Polito, F.; Di Stefano, V.; Minutoli, L.; Atteritano, M.; Levy, R.; Frisina, N.; et al. Efficacy of genistein aglycone on some cardiovascular risk factors and homocysteine levels: A follow-up study. *Nutr. Metab. Cardiovasc. Dis.* **2010**, *20*, 332–340. [\[CrossRef\]](#)
- Marini, H.; Polito, F.; Adamo, E.B.; Bitto, A.; Squadrito, F.; Benvenga, S. Update on genistein and thyroid: An overall message of safety. *Front. Endocrinol.* **2012**, *3*, 94. [\[CrossRef\]](#)
- Marini, H.; Bitto, A.; Altavilla, D.; Burnett, B.P.; Polito, F.; Di Stefano, V.; Minutoli, L.; Atteritano, M.; Levy, R.M.; D'Anna, R.; et al. Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: A follow-up study. *J. Clin. Endocrinol. Metab.* **2008**, *93*, 4787–4796. [\[CrossRef\]](#)
- De Gregorio, C.; Marini, H.; Alibrandi, A.; Di Benedetto, A.; Bitto, A.; Adamo, E.B.; Altavilla, D.; Irace, C.; Di Vieste, G.; Pancaldo, D.; et al. Genistein Supplementation and Cardiac Function in Postmenopausal Women with Metabolic Syndrome: Results from a Pilot Strain-Echo Study. *Nutrients* **2017**, *9*, 584. [\[CrossRef\]](#)
- Irace, C.; Marini, H.R.; Bitto, A.; Altavilla, D.; Polito, F.; Adamo, E.B.; Arcoraci, V.; Minutoli, L.; Di Benedetto, A.; Di Vieste, G. Genistein and endothelial function in postmenopausal women with metabolic syndrome. *Eur. J. Clin. Invest.* **2013**, *43*, 1025–1031. [\[CrossRef\]](#)
- Squadrito, F.; Marini, H.; Bitto, A.; Altavilla, D.; Polito, F.; Adamo, E.B.; D'Anna, R.; Arcoraci, V.; Burnett, B.P.; Minutoli, L.; et al. Genistein in the metabolic syndrome: Results of a randomized clinical trial. *J. Clin. Endocrinol. Metab.* **2013**, *98*, 3366–3374. [\[CrossRef\]](#)
- Dinu, M.; Pagliai, G.; Sofi, F. A Heart-Healthy Diet: Recent Insights and Practical Recommendations. *Curr. Cardiol. Rep.* **2017**, *19*, 95. [\[CrossRef\]](#)

21. Dinu, M.; Pagliai, G.; Angelino, D.; Rosi, A.; Dall'Asta, M.; Bresciani, L.; Ferraris, C.; Guglielmetti, M.; Godos, J.; Del Bo', C.; et al. Effects of Popular Diets on Anthropometric and Cardiometabolic Parameters: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials. *Adv. Nutr.* **2020**, *11*, 815–833. [[CrossRef](#)]
22. Ma, L.; Liu, G.; Ding, M.; Zong, G.; Hu, F.B.; Willett, W.C.; Rimm, E.B.; Manson, J.E.; Sun, Q. Isoflavone Intake and the Risk of Coronary Heart Disease in US Men and Women: Results From 3 Prospective Cohort Studies. *Circulation* **2020**, *141*, 1127–1137. [[CrossRef](#)]
23. Kim, I.S. Current Perspectives on the Beneficial Effects of Soybean Isoflavones and Their Metabolites for Humans. *Antioxidants* **2021**, *10*, 1064. [[CrossRef](#)]
24. Carnethon, M.R.; Khan, S.S. A Feast of Observations about Diet. *Circulation* **2020**, *7*, 1138–1140. [[CrossRef](#)]
25. Sánchez-Martínez, L.; Periago, M.J.; García-Alonso, J.; García-Conesa, M.T.; González-Barrio, R.A. Systematic Review of the Cardiometabolic Benefits of Plant Products Containing Mixed Phenolics and Polyphenols in Postmenopausal Women: Insufficient Evidence for Recommendations to This Specific Population. *Nutrients* **2021**, *13*, 4276. [[CrossRef](#)]